Biocon · NSE: BIOCON · BSE: 532523

Q4 FY22 results · Jan–Mar 2022

Biocon reported revenue from operations of ₹2,408.80 crore (up 31.0% from Q4 FY21) and net profit of ₹283.90 crore (down 4.2% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	2,408.80	1,838.70	+31.0%	2,174.20	+10.8%
Other income	67.30	205.40	−67.2%	48.30	+39.3%
Total income	2,476.10	2,044.10	+21.1%	2,222.50	+11.4%
Profit before share of associates & JVs and tax	395.50	435.60	−9.2%	316.10	+25.1%
Share of profit/(loss) of associates & JVs	(53.00)	(69.50)		(47.20)
Net profit for the period	283.90	296.40	−4.2%	219.60	+29.3%
Attributable to shareholders of the company	238.60	253.20	−5.8%	187.10	+27.5%
EPS, basic (₹)	2.00	2.13	−6.1%	1.57	+27.4%
Net margin (%)	11.8	16.1		10.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	517.70	491.60	+5.3%	473.00	+9.5%
Other income	60.80	44.90	+35.4%	36.70	+65.7%
Total income	578.50	536.50	+7.8%	509.70	+13.5%
Profit before tax	59.20	86.30	−31.4%	43.30	+36.7%
Net profit for the period	38.10	67.70	−43.7%	25.50	+49.4%
EPS, basic (₹)	0.32	0.57	−43.9%	0.21	+52.4%
Net margin (%)	7.4	13.8		5.4

Consolidated

Filed with BSE: 30 Apr 2022, 12:59 IST
Board meeting: 28 Apr 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Apr 2022, 12:59 IST
Board meeting: 28 Apr 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE